Quantcast

Latest Graft-versus-host disease Stories

2011-12-01 13:10:16

Study has implications for treatment of other immune-mediated disorders In a study that seems to pivot on a paradox, scientists at Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients. The effect, in some cases, was profound. The phase I study, published in the Dec. 1 issue of the New England Journal of Medicine, involved allogeneic (donor)...

Cord Blood Treatment Receives FDA Approval
2011-11-11 09:59:21

US drug regulators for the first time have approved a therapy using cells of human blood from the placenta and the umbilical cord to treat cancer or blood-forming disorders, reports ABC News. The US Food and Drug Administration (FDA) on Thursday officially licensed HEMACORD (Hematopoietic Progenitor Cells-Cord, HPC-C) for “use in unrelated donor hematopoietic progenitor cell transplantation procedures“¦ in patients with disorders affecting the hematopoietic system that...

2011-11-02 08:42:28

Older patients with advanced hematologic malignancies, such as leukemia and lymphoma, who received a conditioning regimen that included minimal-intensity radiation therapy prior to allogeneic (genetically different) hematopoietic cell transplantation (HCT; receipt of bone marrow or stem cells transplant) had survival and progression-free survival outcomes suggesting that this treatment approach may be a viable option for older patients with these malignancies, according to a study in the...

2011-11-01 21:26:56

Study details outcomes of patients who received the 'mini transplant' developed at Fred Hutchinson Cancer Research Center Age alone no longer should be considered a defining factor when determining whether an older patient with blood cancer is a candidate for stem cell transplantation. That's the conclusion of the first study summarizing long-term outcomes from a series of prospective clinical trials of patients age 60 and over who were treated with the mini-transplant, a "kinder, gentler"...

2011-10-31 22:47:51

Graft-versus-host disease (GVHD) is a serious risk in many kinds of cell transplants, including for stem cell transplants carried out when stem cells are partially depleted of conventional T cells, which play an important role in the immune system. Now, researchers at Moffitt Cancer Center have tested a process by which T regulatory cells (Tregs) can be "expanded" to help prevent GVHD. "Tregs play a dominant role in transplantation tolerance," said Claudio Anasetti, M.D., corresponding...

2011-08-17 08:52:00

NEW YORK, Aug. 17, 2011 /PRNewswire/ -- Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed by the Hadassah University Hospital, Israel's foremost medical research center, announced that its portfolio company Enlivex Therapeutics (92% owned by Hadasit Bio) has completed the recruitment of three out of four groups in its Phase I / II clinical trial using its treatment for the reduction of graft versus...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.